Please assess the completion status of the following clinical trial:

Trial Title: Treating Postmenopausal Dyspareunia Where it Hurts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal women aged 40 to 70 years old.~2. Postmenopausal, demonstrated by at least one of the following:~   i. Cessation of menses for ≥1 years if age is \>50 ii. Bilateral oophorectomy iii. A history of climacteric symptoms if below age 50, having an ovary and scarred or absent uterus.~3. Onset of dyspareunia after menopause.\*~4. Stable heterosexual partnership ≥2 years (or by investigator discretion if less than 2 years) and both partners want to have more satisfying penetrative intimacy.~5. No estrogen product use, local or systemic, for 6 months.\*~6. More than 6 months of consistent insertional pain with intercourse (may have stopped having intercourse due to this consistent experience of pain).\*~7. Willingness to enter a study where she will receive low-dose local estrogen.\*~8. Willingness to enter a study that requires application of cream on a frequent schedule for 3 months. \*~9. Willingness to evaluate the progress of therapies by use of the Tampon Test as many as 2 times per week, and willingness to attempt intercourse if the Tampon Test indicates tolerable penetrative pain.\*~   * n/a for reference group~Exclusion Criteria:~1. Consistently has pain in the pelvis or low abdomen during or after intercourse (deep dyspareunia).~2. Negative cotton-swab touch test in the vulvar vestibule or vestibular tenderness that is not extinguishable by application of lidocaine 4% topical solution applied for 3 minutes.~3. Partner with sexual dysfunction limiting his performance or making it inconsistent. (The use of male therapy for erectile dysfunction is acceptable.)~4. Diagnosis by a physical therapist or clinician of significant pelvic floor muscle tension causing pain (pelvic floor myalgia) or has been found on screening examination to have pelvic floor tenderness or bladder tenderness.~5. Constant burning pain localized to the vulva.~6. Allergy to local estrogen products or lidocaine numbing agents.~7. Previous estrogen receptor positive breast cancer or endometrial cancer.~8. Endometrial thickness ≥5mm on screening via transvaginal ultrasound.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 50mcg estradiol cream (Type: ACTIVE_COMPARATOR): Subjects randomized to 50mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
- 100mcg estradiol cream (Type: ACTIVE_COMPARATOR): Subjects randomized to 100mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump

Based on this trial design, predict the completion outcome and termination type (if applicable).